ZNF217 a new prognostic and predictive biomarker of recurrent invasive and metastatic phenotypes in breast cancer
US8709719B2 · kind B2 · utility
0Cited by
0References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 19, 2010 |
| Grant date | Apr 29, 2014 |
| Priority date | — |
| Expiry date | Sep 8, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to methods for determining the prognosis of a cancer. The methods involve determining the level of expression of the ZNF217 gene in a cancer cell sample or in a tumor sample wherein over-expression of ZNF217 is correlated with likelihood of metastasis and with likelihood of relapse/recurrence of the cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.